Oxcarbazepine

For the highly prevalent neurological disorder epilepsy, clinical practice has long been plagued by the pain points of numerous adverse reactions and complex drug interactions associated with traditional antiepileptic drugs, while the advent of oxcarbazepine provides a better option for the long-term management of such patients. As a second-generation dibenzazepine antiepileptic drug, it is the 10-keto derivative of carbamazepine. It stabilizes the hyperexcitable neuronal cell membrane by blocking voltage-dependent sodium channels, and exerts an anticonvulsant effect by regulating calcium channels at the same time. Compared with first-generation products, it has a lighter burden on liver and kidney metabolism and fewer drug interactions. In addition to being applicable to monotherapy or adjunctive therapy of partial epileptic seizures and generalized tonic-clonic seizures in adults and children over 4 years old, it can also be used as second-line therapy for trigeminal neuralgia, and is particularly suitable for childbearing-age women and elderly patients who require long-term medication.

Oxcarbazepine is one of the core varieties in the global antiepileptic market. In 2023, its global market size was approximately USD 1.28 billion, and its domestic market size exceeded RMB 1.8 billion, with a compound annual growth rate of 6.2% in the past three years, which is higher than the growth rate of the overall antiepileptic drug market. In terms of the competitive landscape, the domestic preparation market has formed a situation where the original drug and generic drugs coexist. At present, oxcarbazepine preparations from more than 20 enterprises have passed the consistency evaluation, and this variety has been included in the 7th batch of national centralized drug procurement, with an average price reduction of over 60% for winning bids, which has greatly improved clinical accessibility and driven the continuous rise of market demand for upstream active pharmaceutical ingredients.

The original developer of oxcarbazepine is Novartis, with the trade name Trileptal. Its compound patent for the US market expired in 2019, and its core patent in China has also expired. The main dosage forms approved for the original drug include tablets (150mg, 300mg, 600mg) and oral suspension (60mg/ml), all relevant dosage forms have been included in the China List of Marketed Drugs and the FDA Reference Preparations List. In terms of domestic API registration, at present, oxcarbazepine APIs from more than 15 enterprises have obtained CDE registration numbers, among which more than 10 registered varieties are in A status, and oral preparations and sustained-release preparations from multiple enterprises have been approved for marketing. (Data as of October 2024, please refer to the official CDE website for the latest information)

As a compliant supplier deeply engaged in the pharmaceutical reference standard sector, CATO can provide a full set of impurity reference standards for oxcarbazepine API. All products meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. Most varieties are in sufficient stock, and in-stock products ordered before 16:00 can be shipped on the same day, which can fully meet the full-scenario needs of pharmaceutical enterprises for R&D, quality research and routine quality inspection.